A press release by the industry states that women with osteoporosis after menopause who receive denosumab in their first-line treatment have a lower fracture risk than those who use alendronate.
Researchers analyzed data collected from U.S. Medicare recipients of postmenopausal woman with osteoporosis who had no prior treatment history. The data showed women taking denosumab for multiple fractures had lower risk than those who did not.
